Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics

Longboard Pharmaceuticals, Inc., (LBPH): $18.86

0.22 (-1.15%)

POWR Rating

Component Grades








Add LBPH to Watchlist
Sign Up

Industry: Biotech




#298 of 355

in industry

LBPH Price/Volume Stats

Current price $18.86 52-week high $28.15
Prev. close $19.08 52-week low $3.60
Day low $18.71 Volume 125,415
Day high $20.13 Avg. volume 978,363
50-day MA $19.45 Dividend yield N/A
200-day MA $13.99 Market Cap 733.28M

LBPH Stock Price Chart Interactive Chart >

Longboard Pharmaceuticals, Inc., (LBPH) Company Bio

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.

LBPH Latest News Stream

Event/Time News Detail
Loading, please wait...

LBPH Latest Social Stream

Loading social stream, please wait...

View Full LBPH Social Stream

Latest LBPH News From Around the Web

Below are the latest news stories about LONGBOARD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LBPH as an investment opportunity.

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

LA JOLLA, Calif., November 29, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neu

Yahoo | November 29, 2023

Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)

Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 24, 2023

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

LA JOLLA, Calif., November 21, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of Developmental and Epileptic Encephalopathies (DEEs), in poster sessions at the 2023 AES Annual Meeting. Longboard will also host a

Yahoo | November 21, 2023

Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock Picks

In this article, we discuss Farallon Capital: a global and diversified hedge fund and its top stock picks. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Farallon Capital. Risk arbitrage or merger arbitrage is one of the most popular strategies that hedge funds […]

Yahoo | November 13, 2023

Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade

The consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 8, 2023

Read More 'LBPH' Stories Here

LBPH Price Returns

1-mo -5.37%
3-mo -0.16%
6-mo 275.70%
1-year 161.94%
3-year 94.23%
5-year N/A
YTD 212.77%
2023 84.97%
2022 -33.20%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!